These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 20413326)

  • 61. The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor.
    Abastado JP
    Cancer Res; 2012 May; 72(9):2159-61. PubMed ID: 22549945
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Composite peptide-based vaccines for cancer immunotherapy (Review).
    Yang J; Zhang Q; Li K; Yin H; Zheng JN
    Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Development of novel genetic cancer vaccines based on membrane-attached β2 microglobulin.
    Cafri G; Margalit A; Tzehoval E; Eisenbach L; Gross G
    Ann N Y Acad Sci; 2013 Apr; 1283():87-90. PubMed ID: 23387369
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The repertoire of human tumor-associated epitopes--identification and selection of antigens and their application in clinical trials.
    Haen SP; Rammensee HG
    Curr Opin Immunol; 2013 Apr; 25(2):277-83. PubMed ID: 23619309
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
    Chen X; Yang J; Wang L; Liu B
    Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cyclins against cancer: a novel family of tumor antigens?
    Klein-González N; Kondo E; von Bergwelt-Baildon MS
    Immunotherapy; 2010 Sep; 2(5):595-7. PubMed ID: 20874640
    [No Abstract]   [Full Text] [Related]  

  • 67. Challenges and advances towards the rational design of mRNA vaccines.
    Pollard C; De Koker S; Saelens X; Vanham G; Grooten J
    Trends Mol Med; 2013 Dec; 19(12):705-13. PubMed ID: 24138818
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
    Gaidzik N; Westerlind U; Kunz H
    Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic.
    Singh R; Wallecha A
    Hum Vaccin; 2011 May; 7(5):497-505. PubMed ID: 21422819
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade.
    D'Alise AM; Leoni G; Cotugno G; Troise F; Langone F; Fichera I; De Lucia M; Avalle L; Vitale R; Leuzzi A; Bignone V; Di Matteo E; Tucci FG; Poli V; Lahm A; Catanese MT; Folgori A; Colloca S; Nicosia A; Scarselli E
    Nat Commun; 2019 Jun; 10(1):2688. PubMed ID: 31217437
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Current status and future prospects of peptide-based cancer vaccines.
    Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
    Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rational design of vaccines: learning from immune evasion mechanisms of persistent viruses and tumors.
    Arens R
    Adv Immunol; 2012; 114():217-43. PubMed ID: 22449784
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
    Butt AQ; Mills KH
    Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cancer vaccines.
    Pardoll DM
    Immunol Today; 1993 Jun; 14(6):310-6. PubMed ID: 8397772
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
    Wang HY; Wang RF
    Adv Immunol; 2012; 114():151-76. PubMed ID: 22449781
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Tumor vaccines and peptide-loaded dendritic cells (DCs)].
    Schummer V; Flindt S; Hinz T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1254-8. PubMed ID: 26349562
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cancer vaccines inducing antibody production: more pros than cons.
    Jensen-Jarolim E; Singer J
    Expert Rev Vaccines; 2011 Sep; 10(9):1281-9. PubMed ID: 21919618
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Human Tumor Antigens and Cancer Immunotherapy.
    Vigneron N
    Biomed Res Int; 2015; 2015():948501. PubMed ID: 26161423
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
    Nelson B
    Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.